← Browse by Condition
Medical Condition

tislelizumab

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT07136077 Phase 2
Recruiting

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Enrollment
20 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →